[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341608-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341608-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","selective-p300-degradation-via-peptide-protac-a-new-therapeutic-strategy-for-advanced-prostate-cancers","Selective p300 Degradation via Peptide PROTAC: A New Therapeutic Strategy for Advanced Prostate Cancers","","p300 and its paralog CBP act as essential transcriptional coactivators in prostate cancer by supporting androgen receptor (AR)-dependent acetylation and enhancer-driven cancer-specific transcription. Conventional HAT/BRD inhibitors incompletely block p300/CBP function, motivating targeted protein degradation (TPD) using peptide PROTACs. A CH1-domain peptide PROTAC reports selective p300 degradation, reduces AR/AR-V7 target gene expression, down-regulates c-Myc and FOXA1, and activates p53. MDM2-binding design and selenium nanoparticle incorporation improve antitumor efficacy and tumor accumulation, with strong activity in AR-positive and AR-independent models, including NEPC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/selective-p300-degradation-via-peptide-protac-a-new-therapeutic-strategy-for-advanced-prostate-cancers/341608/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/selective-p300-degradation-via-peptide-protac-a-new-therapeutic-strategy-for-advanced-prostate-cancers/341608.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is p300 targeted in advanced prostate cancer?","Question",{"text":63,"@type":64},"p300/CBP are required coactivators for androgen receptor transcriptional activity and support oncogenic factors through histone and non-histone acetylation programs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the peptide PROTAC achieve selective p300 degradation?",{"text":68,"@type":64},"The reported design uses a peptide binder to p300’s CH1 domain and an E3 ligase module that enables MDM2-dependent targeted protein degradation rather than simple domain inhibition.",{"name":70,"@type":61,"acceptedAnswer":71},"What antitumor responses were observed across different prostate cancer contexts?",{"text":72,"@type":64},"The p300 PROTAC shows strong anti-proliferative effects in both AR-positive and AR-independent cells, including NEPC models, while activating p53 and reducing AR-related and NE lineage markers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341608,1790192925,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":97,"preview_page_count":26,"preview_urls":144},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Comment   \nSelective p300 degradation via peptide PROTAC: a new therapeutic strategy for advanced prostate cancers  \nLing-Yu Wanga,b,c,∗  \naDepartment of Biochemistry and Molecular Biology, Chang Gung University, Taoyuan 33302, Taiwan bDivision of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan cGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan  \np300 and its paralog CREB-binding protein (CBP) are essential coactivators for many cancer-associated transcription factors. In prostate cancer, the transcriptional activity of the androgen receptor (AR) relies on p300/ CBP, which catalyzes AR acetylation to enhance coactivator binding, and deposits histone acetylation at target enhancers to program a cancer-speciﬁc AR-dependent transcriptome.1–3 Additionally, the expression ofAR and various tumor-promoting factors, such as c-Myc and FOXA1, also depends on p300 and super enhancer activities.3–6 These essential tumorigenic roles of p300/ CBP make them promising therapeutic targets for prostate cancer treatment.  \np300 and CBP are large proteins containing multiple domains, including the catalytic histone acetyltransferase (HAT) writer domain, a bromodomain (BRD) reader domain, three cysteine/histidine-rich domains (CH1 to CH3), and several other domains. Due to the sequence and functional similarity between p300 and CBP, conventional small-molecule inhibitors typically cross-react with both enzymes. Despite these similarities, functional evidence and chromatin binding analyses indicate distinct roles for p300 and CBP in various cell types, including prostate cancer.3,4,7 Given that conventional inhibitors targeting either the HAT or BRD domain incompletely hinder the oncogenic activity of p300/CBP, targeted protein degradation (TPD) via proteolysistargeting chimera (PROTAC) technology has emerged as a promising approach in recent p300/CBP drug discovery.8 Several small-molecule-based p300/CBP PROTACs have been reported in recent years. Among them, JQAD-1 is the only PROTAC showing preferred degradation selectivity towards p300 .9  \nRecently published in eBioMedicine, Zhang et [al. re](al. re)ported the ﬁrst peptide-based PROTAC targeting p300 via its CH1 domain.10 Peptide drugs offer advantages in increased speciﬁcity and efﬁcacy due to their capacity for larger interacting surfaces with binding partners. The peptide p300 PROTAC reported by Zhang et al. shows speciﬁc degradation efﬁciency against p300 but not  \n*Corresponding author. Department of Biochemistry and Molecular Biology, Chang Gung University, No.259, Wenhua 1st Rd., Guishan District, Taoyuan City 33302, Taiwan.  \nE-mail address: [lywang@mail.cgu.edu.tw](lywang@mail.cgu.edu.tw).  \n© 2024 The Author(s) . Published by Elsevier B.V. This is an open access article under the CC BY-NC license ([http://creativecommons.org/](http://creativecommons.org/)[ ](http://creativecommons.org/)[licenses/by-nc/4.0/](licenses/by-nc/4.0/)) .  \nCBP. Additionally, the E3 ligase moiety design employs an MDM2-binding peptide that partially aligns with the MDM2-p53 interface, potentiating p53 release and activation for enhanced antitumor activity. To increase drug stability and membrane penetration, the research group incorporated selenium nanoparticles into the peptide molecule, successfully demonstrating drug accumulation within tumors, possibly due to an enhanced permeability and retention effect.  \nGiven the coactivating roles of p300/CBP in AR signaling, the antitumor effect of p300/CBP inhibition is considered to be greater in AR-positive cells compared to AR-independent cells.4 Remarkably, using the peptide p300 PROTAC, Zhang et al. demonstrated strong anti-proliferative potency in both AR-positive and ARnegative prostate cancer cells, including highly malignant neuroendocrine differentiated models (NEPC) . Speciﬁcally, they showed that the compound not only effectively decreases the expression of AR","cbCaisArOL9DbyjM","https://ap.wps.com/l/cbCaisArOL9DbyjM","pdf",151563,"English","# p300/CBP as prostate cancer coactivators\n## AR signaling and enhancer acetylation\n# Limitations of conventional p300/CBP inhibition\n# Peptide PROTAC strategy targeting p300\n## CH1-domain peptide PROTAC\n## MDM2-dependent TPD and p53 activation\n## Selenium nanoparticles and tumor accumulation\n# Antitumor effects across AR and lineage statuses\n## AR-positive versus AR-independent models\n## NEPC and lineage marker reduction\n# Key implications and outlook","[{\"question\":\"Why is p300 targeted in advanced prostate cancer?\",\"answer\":\"p300/CBP are required coactivators for androgen receptor transcriptional activity and support oncogenic factors through histone and non-histone acetylation programs.\"},{\"question\":\"How does the peptide PROTAC achieve selective p300 degradation?\",\"answer\":\"The reported design uses a peptide binder to p300’s CH1 domain and an E3 ligase module that enables MDM2-dependent targeted protein degradation rather than simple domain inhibition.\"},{\"question\":\"What antitumor responses were observed across different prostate cancer contexts?\",\"answer\":\"The p300 PROTAC shows strong anti-proliferative effects in both AR-positive and AR-independent cells, including NEPC models, while activating p53 and reducing AR-related and NE lineage markers.\"}]","Selective p300 Degradation via Peptide PROTAC: A New Therapeutic Strategy for Advanced Prostate Cancers | PDF",1790042797,[145,149],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f7ef1f779a0a19eaf6d108ed0f0cfba.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5626351f108144e91f3c51f63658de12.webp",982,1309]